Literature DB >> 28861597

Single high dose versus repeated bone-targeted radionuclide therapy.

K Liepe1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28861597     DOI： 10.1007/s00259-017-3815-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  8 in total

1.  Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Authors:  Fred Saad; Joan Carles; Silke Gillessen; Axel Heidenreich; Daniel Heinrich; Jeremy Gratt; Jérémy Lévy; Kurt Miller; Sten Nilsson; Oana Petrenciuc; Marcello Tucci; Manfred Wirth; Judith Federhofer; Joe M O'Sullivan
Journal:  Lancet Oncol       Date:  2016-07-26       Impact factor: 41.316

2.  A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.

Authors:  J M O'Sullivan; A R Norman; V R McCready; G Flux; F M Buffa; B Johnson; J Coffey; G Cook; J Treleaven; A Horwich; R A Huddart; C C Parker; D P Dearnaley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-30       Impact factor: 9.236

3.  Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Authors:  S M Tu; R E Millikan; B Mengistu; E S Delpassand; R J Amato; L C Pagliaro; D Daliani; C N Papandreou; T L Smith; J Kim; D A Podoloff; C J Logothetis
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

4.  Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.

Authors:  Hans-Jürgen Biersack; Holger Palmedo; Andrej Andris; Stefan Rogenhofer; Furn F Knapp; Stefan Guhlke; Samer Ezziddin; Jan Bucerius; Dirk von Mallek
Journal:  J Nucl Med       Date:  2011-10-05       Impact factor: 10.057

Review 5.  Palliative radiotherapy in the treatment of skeletal metastases.

Authors:  Tiina Saarto; Rita Janes; Mikko Tenhunen; Mauri Kouri
Journal:  Eur J Pain       Date:  2002       Impact factor: 3.931

6.  Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.

Authors:  Christopher Parker; Steven E Finkelstein; Jeff M Michalski; Joe M O'Sullivan; Øyvind Bruland; Nicholas J Vogelzang; Robert E Coleman; Sten Nilsson; Oliver Sartor; Rui Li; Monica A Seger; David Bottomley
Journal:  Eur Urol       Date:  2016-06-22       Impact factor: 20.096

7.  Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.

Authors:  Ana M Denis-Bacelar; Sarah J Chittenden; David P Dearnaley; Antigoni Divoli; Joe M O'Sullivan; V Ralph McCready; Bernadette Johnson; Yong Du; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-21       Impact factor: 9.236

8.  High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.

Authors:  J M O'Sullivan; V R McCready; G Flux; A R Norman; F M Buffa; S Chittenden; M Guy; K Pomeroy; G Cook; J Gadd; J Treleaven; A Al-Deen; A Horwich; R A Huddart; D P Dearnaley
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640
  8 in total
  1 in total

1.  Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.

Authors:  Ana M Denis-Bacelar; Sarah J Chittenden; David P Dearnaley; Antigoni Divoli; Joe M O'Sullivan; V Ralph McCready; Bernadette Johnson; Yong Du; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.